NDLI: Gezielter Einsatz des Tumormarkers PSA.

Please wait, while we are loading the content...

Verbesserte Sensitivität bei Nieren- und Harnwegserkrankungen durch Kombination von Teststreifen, automatisiertem bzw. standardisiertem Urinsediment und differenzierter Proteinbestimmung im Urin.

Die Rolle des Labors in der Diagnostik und Verlaufskontrolle der Osteoporose.

Alte und neue Eisenparameter - Bedeutung im Eisenstoffwechsel und in der Diagnostik.

Diagnostik der Autoimmunerkrankungen.

Die Bedeutung der Präanalytik.

Monitoring von Immunsuppressiva.

Laboratoriumsmedizinische Strategien in der endokrinologischen Diagnostik ovarieller Störungen.

Procalcitonin und seine Bedeutung für die Diagnose bakterieller Infektionen.

Year: 2008 Volume: 65 Issue: 8

Year: 2008 Volume: 65 Issue: 7

Year: 2008 Volume: 65 Issue: 6

Year: 2008 Volume: 65 Issue: 5

Year: 2008 Volume: 65 Issue: 4

Gezielter Einsatz des Tumormarkers PSA.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Kwiatkowski, Maciej Stieber, Petra Huber, Andreas R. Recker, Franz
Description	Author Affiliation: Kwiatkowski M ( Urologische Klinik, Kantonsspital Aarau. maciej.kwiatkowski@ksa.ch)
Abstract	UNLABELLED: Tumor markers are being used in the early detection of cancer disease, diagnostics, prognosis, therapy and disease follow-up. A lot of clinical studies would not be nowadays possible without tumor markers. As in clinical practice the informative value of results is limited (by limited sensitivity and/or specificity) those markers should be selectively used, i.e. in such clinical setting where there is a clear benefit. Prostate specific antigen (PSA) has become the most important tumor marker in oncology. Its importance ranges from early detection of prostate cancer until therapy decision making in hormone refractory cancer. To prevent initial PSA- 'terrorism' in early detection the patient must be well informed about risk of prostate cancer and therapeutic options inclusively possible side effects. Does the man at risk agree further evaluation by biopsy has to be performed directly above a PSA-cut-off 4.0 ng/ml. A high percentage of free PSA is not allowed to prolong diagnostic procedure. On the opposite, in PSA range 3.0-3.9 ng/ml and free-to-total PSA ratio less than 12% a prostate biopsy is also indicated. The diagnostic 'grey zone' 4.0-10 ng/ml does not exist any more. Further follow-up should be done if the estimated life expectancy exceeds 10 years and should be performed in the PSA-range 2.0-3.9 ng/ml annually, in the PSA-range 1.0-1.9 ng/ml biannually and in the PSA range less that 1.0ng/ml triennially. About 3-25% of newly detected cancers are clinically insignificant. Models based on PSA, Gleason Score and tumor load of biopsies are helpful in identifying these men for 'active surveillance' in curative intent. IN CONCLUSION: 'Not every early detected cancer must be cured, but cancer where cure is necessary, must be early detected!' After primary therapy (operation/radiotherapy) one third of men will document a PSA only relapse. 30% of them will develop clinical symptoms and possible die from disease. PSA and especially PSA doubling time is a promising marker to identify these men at risk for whom salvage-radiotherapy, salvage prostatectomy or hormonal therapy can be an option. However the benefit in survival must be weight against a possible loss in quality of life.
File Format	HTM / HTML
ISSN	00405930
Issue Number	9
Volume Number	65
e-ISSN	16642864
Journal	Therapeutische Umschau
Language	German
Publisher	Hogrefe Verlag
Publisher Date	2008-09-01
Publisher Place	Switzerland
Access Restriction	Subscribed
Subject Keyword	Discipline Therapeutics Tumor Markers, Biological Blood Neoplasm Proteins Prostate-specific Antigen Prostatic Neoplasms Diagnosis Humans Male Epidemiology Reproducibility Of Results Sensitivity And Specificity English Abstract Journal Article Review
Alternative Title	Selective application of tumor markers PSA
Content Type	Text
Resource Type	Article
Subject	Medicine

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in